Robert P. Mauch, poised to become the third CEO in Cencora’s 23-year history, brings a wealth of experience and a deep understanding of the company’s operations. His leadership has been ...

Cencora (NYSE:COR) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ratings, shedding ...

Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. CONSHOHOCKEN, Pa ...

Investors might want to bet on Cencora (COR), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the ...

Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments.

PharmaLex is now part of Cencora, a leading global pharmaceutical solutions organization centered on improving lives around the world. PharmaLex adds to Cencora’s expanding suite of pharma solutions ...

Cencora, Inc. (COR), headquartered in Pennsylvania, is a global pharmaceutical sourcing and distribution leader offering innovative healthcare solutions and services. With a market cap of $45.2 ...